Using differential mRNA display, we isolated differentially expressed genes after stimulation of angiotensin II (Ang II) type 2 (AT(2)) receptors in PC12w cells. Among the polymerase chain reaction products isolated, we identified Zfhep, a zinc finger homoeodomain enhancer-binding protein and the angiotensin AT(2) receptor itself, both implicated in developmental processes. In the presence of e...

OBJECTIVE Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure. A role for increased ventricular wall stress, associated with arterial hypertension, that ca...

Ciobica Alin »Alexandru Ioan Cuza« University Dept. of Biology B dul Carol I, 11 700506, Iasi, Romania Tel :0040751218264; Fax 0040232201472 e-mail: alin.ciobicaauaic.ro Summary: It has already been demonstrated that a complete brain renin–angiotensin system (RAS) exists distinctly separate from the peripheral system and is implicated in complex functions such as memory, emotional responses and...

The angiotensin AT2 receptor is an atypical seven transmembrane domain receptor that is coupled to activation of tyrosine phosphatase and inhibition of MAP kinase, and does not undergo agonist-induced internalization. An investigation of the occurrence and nature of AT2 receptor phosphorylation revealed that phorbol ester-induced activation of protein kinase C (PKC) in HA-AT2 receptor-expressin...

Response We are not surprised by the very sensible question from Achard et al as to why selective AT1 receptor antagonists were not used in our experiments reported in Stroke.1 The reason for this decision is academically somewhat disappointing while unfortunately very relevant in the current era, with an increased awareness of the real value of intellectual property. Our request for losartan t...

Response We are not surprised by the very sensible question from Achard et al as to why selective AT1 receptor antagonists were not used in our experiments reported in Stroke.1 The reason for this decision is academically somewhat disappointing while unfortunately very relevant in the current era, with an increased awareness of the real value of intellectual property. Our request for losartan t...

Response We are not surprised by the very sensible question from Achard et al as to why selective AT1 receptor antagonists were not used in our experiments reported in Stroke.1 The reason for this decision is academically somewhat disappointing while unfortunately very relevant in the current era, with an increased awareness of the real value of intellectual property. Our request for losartan t...